How long drug registration review takes in China
The Drug Registration Measures set a review period of 200 working days for a marketing application and 60 for a clinical trial application.1 The administrative decision follows within 20 working days, and the certificate within 10 more.1 Since September 2025 a qualifying clinical trial application for an innovative drug is reviewed within 30 working days.2
Each period is the longest time allowed for one step. Article 125 counts the periods in working days, and Article 103 leaves four kinds of time out of them.1
The periods step by step
| Step | Period in working days |
|---|---|
| Formal check, with a decision to accept, require correction or refuse | 5 |
| Review and approval of a clinical trial application | 60 |
| Review of a marketing application | 200 |
| Review of a marketing application under priority review | 130 |
| Priority review of a rare disease drug in urgent clinical need and marketed abroad | 70 |
| Review of a stand-alone application for a generic chemical active ingredient | 200 |
| Approval of the generic name | 30 |
| Suitability review of a non-prescription drug | 30 |
| Re-registration | 120 |
| Administrative decision | 20 |
| Issue and delivery of the certificate | 10 |
A supplementary application during a clinical trial has the same 60 working days as the trial application.1 The review of a related application, such as an ingredient reviewed with a preparation, takes the period of the preparation.1
Supplementary applications after marketing
Article 96 sets three periods for a supplementary application that requires approval.1
| Supplementary application | Period in working days |
|---|---|
| A single change | 60 |
| Several changes filed together | 80 |
| A change involving review of trial data, or inspection and testing | 200 |
Clinical trials
The Drug Administration Law fixes the period for a clinical trial application in statute. The regulator decides within 60 working days of acceptance and notifies the sponsor. Where no notice is given in that time, consent is deemed given.3
No new technical materials may be added while a clinical trial application is under review. Where new research is needed, the applicant may withdraw and apply again.1
The 30-working-day channel
The National Medical Products Administration issued Announcement No. 86 of 2025 on 9 September 2025, in force from publication. A qualifying clinical trial application for an innovative drug is reviewed and approved within 30 working days of acceptance.2
The application must be for a trial of a Class 1 innovative drug, whether a traditional Chinese medicine, a chemical drug or a biological product. It must also meet one of three conditions.2
- It is a key innovative drug of clear clinical value that is supported under the national policy of support for innovative drugs.
- It is an innovative paediatric drug, rare disease drug or traditional Chinese medicine published as qualifying by the Center for Drug Evaluation.
- It is developed globally at the same time.
The third condition covers Phase I and Phase II trials of such a product. It also covers a Phase III international multicentre trial that a principal investigator at a Chinese institution leads or jointly leads.2
The applicant undertakes to start the trial within 12 weeks of approval.2 The Center decides on acceptance within 5 working days. Where a difficult question requires a technical consultation or an expert meeting, the Center tells the applicant within 20 working days of acceptance. The period of 60 working days then applies.2
Inspection and testing
Inspection and testing run inside the review period and have their own periods.1
| Step | Period in working days |
|---|---|
| Notice from the Center for Drug Evaluation to start inspection | Within 40 after acceptance |
| Completion of on-site production inspection | In principle 40 before the review period ends |
| Sample testing | 60 |
| Sample testing with verification of the standard | 90 |
| Supplementing materials during testing | 30 |
| Testing report to the Center for Drug Evaluation | In principle 40 before the review period ends |
What extends the period
The Center for Drug Evaluation in principle asks for supplementary technical materials once. It lists every question and gives the applicant 80 working days to respond.1 That time is left out of the review period. When the Center has received all of the materials, the review starts again. The review period is then extended by one third, or by one quarter under priority review.1
Where only an explanation of the filed materials is needed, the applicant has 5 working days to provide it.1
A technical body may also extend a period for special circumstances, by up to one half of the original period.1
Time that is left out
Article 103 lists the time that does not count toward a period.1
- time the applicant takes to supplement materials, to rectify after inspection, and to check the production process, quality standard and package insert as required
- delay of inspection, testing or an expert meeting caused by the applicant
- time during which review and approval are suspended under laws and regulations
- time taken by an inspection abroad, where one is started
Pilots under Document 53
An opinion of the General Office of the State Council, dated 30 December 2024, provides for two pilots. A provincial regulator applies and the national regulator agrees.4
| Pilot | Period now | Period in the pilot |
|---|---|---|
| Review and approval of clinical trials of innovative drugs | 60 working days | 30 working days |
| Review of supplementary applications that need inspection and testing | 200 working days | 60 working days |
Questions people also ask
How long is the review of a new drug application in China?
The review period is 200 working days, 130 under priority review, and 70 for a rare disease drug in urgent clinical need that is marketed abroad.1
Is the decision included in the 200 working days?
The administrative decision has its own period of 20 working days, and the certificate is issued within 10 working days after it.1
What happens when the reviewer asks for more data?
The applicant has 80 working days to respond, and that time is left out of the period. The review period is then extended by one third, or by one quarter under priority review.1
Which trials qualify for the 30-working-day channel?
The channel is for clinical trials of Class 1 innovative drugs that meet one of three conditions. The applicant undertakes to start the trial within 12 weeks of approval.2
Does an inspection abroad count toward the period?
Where an inspection abroad is started, the time it takes is left out of the period.1
Footnotes
-
Measures for the Administration of Drug Registration (State Administration for Market Regulation Order No. 27), Articles 87, 88, 94 to 103 and 125. https://www.gov.cn/zhengce/zhengceku/2020-04/01/content_5498012.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17
-
National Medical Products Administration, Announcement on Optimising the Review and Approval of Clinical Trials of Innovative Drugs, No. 86 of 2025. https://yjj.sh.gov.cn/qtgzwj/20250912/c840a6ddf1cf4c58a4855427d0f9f476.html ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7
-
Drug Administration Law of the People’s Republic of China (revised 2019), Article 19. http://www.gd.gov.cn/zwgk/wjk/zcfgk/content/post_2521598.html ↩
-
General Office of the State Council, Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Regulation and Promoting the High-Quality Development of the Pharmaceutical Industry, Guo Ban Fa [2024] No. 53, items 8 and 9. https://www.gov.cn/zhengce/content/202501/content_6996115.htm ↩
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.